Navigation Links
Syndax Pharmaceuticals to Present at BIO Investor Forum
Date:9/28/2010

WALTHAM, Mass., Sept. 28 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the 9th Annual BIO Investor Forum Tuesday, October 5, 2010 at the Palace Hotel in San Francisco.

Dr. Horobin's presentation will be given at 11:30 am PT (2:30 pm ET) and will include an overview of the upcoming milestones including the ongoing phase 2 clinical program for entinostat in breast, lung, colorectal cancer and hematologic malignancies.

The presentation will be available at Syndax's website, www.syndax.com.

About SyndaxSyndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.

Syndax holds rights to entinostat from Bayer Schering Pharma and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit www.syndax.com.Contact InformationJoanna Horobin, M.D.

Danielle Bertrand Syndax Pharmaceuticals, Inc

WCG Tel: 781-419-1402

Tel: 415-946-1056 jhorobin@syndax.com

dbertrand@wcgworld.com
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ... for solid tumor cancers, today announced that yesterday ... announced last Friday, March 17, 2017. ... securities totaling 28,843,692 shares, comprised of 18,843,692 common ... of Class C Warrants pre-funded at the closing ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... , March 23, 2017 NetworkNewsWire ... ... death, putting significant strain on health care systems, in terms ... diagnoses rises, so too does the development of innovative and ... side effects. Among the many types of cancer treatments, a ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
Breaking Biology News(10 mins):